Insider Transactions in Q4 2025 at Replimune Group, Inc. (REPL)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2025
|
Sushil Patel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+27.26%
|
-
|
|
Dec 19
2025
|
Andrew Schwendenman Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+11.33%
|
-
|
|
Dec 19
2025
|
Christopher Sarchi Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+18.13%
|
-
|
|
Dec 19
2025
|
Emily Luisa Hill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+23.59%
|
-
|
|
Dec 19
2025
|
Konstantinos Xynos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+23.1%
|
-
|
|
Dec 09
2025
|
Kapil Dhingra Director |
SELL
Open market or private sale
|
Direct |
3,169
-100.0%
|
$31,690
$10.4 P/Share
|
|
Dec 09
2025
|
Kapil Dhingra Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,169
+50.0%
|
$3,169
$1.75 P/Share
|
|
Dec 02
2025
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,000
-2.91%
|
$110,000
$11.13 P/Share
|
|
Nov 17
2025
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,248
-4.93%
|
$65,232
$9.1 P/Share
|
|
Nov 17
2025
|
Christopher Sarchi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,208
-4.06%
|
$46,872
$9.1 P/Share
|